Targeted therapeutic agents for colorectal cancer. - Wikidata - awgldk - TriplyDB

Targeted therapeutic agents for colorectal cancer.

Targeted therapeutic agents for colorectal cancer.

http://www.wikidata.org/entity/Q37158228

about

Tumour biomarkers: homeostasis as a novel prognostic indicator Evaluating the quality of colorectal cancer care in the state of Florida: results from the Florida Initiative for Quality Cancer Care Exploring Different Strategies for Efficient Delivery of Colorectal Cancer Therapy Mechanisms of resistance to EGFR targeted therapies.Strategies of targeting oral drug delivery systems to the colon and their potential use for the treatment of colorectal cancer.Epidermal growth factor receptor: an important target in esophageal cancer.Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.Lebein, a snake venom disintegrin, suppresses human colon cancer cells proliferation and tumor-induced angiogenesis through cell cycle arrest, apoptosis induction and inhibition of VEGF expression.Identification of novel target proteins in sebaceous gland carcinoma.NF-κB p65 phosphorylated at serine-536 is an independent prognostic factor in Swedish colorectal cancer patients.

P2860

Q28069898-1388C968-05E5-4669-A188-7CF03F8AF208 Q36095244-841BB79B-5B80-474F-947A-E6E218B921EB Q36324618-B55681DD-E416-4D60-8448-EBCA7CAE6907 Q36887721-ECDEE805-4FB3-47C8-B0BF-B8533D7AAD93 Q38017299-5787752F-F1E3-49D7-BC61-3831E372FB26 Q38121640-56E01A5D-82D0-411F-B8FD-BE0E0F1B2622 Q39120155-4A1A2976-71D7-46A1-9508-E71E11FE314D Q40813050-4063D434-05C6-4CED-813D-F5F177F82056 Q43466268-35B0B735-FDEE-46CD-9B19-4B3BDB8AD0C5 Q53204314-2E82C1CA-4C5E-4EA6-B556-42212DDDE8C6

P2860

Targeted therapeutic agents for colorectal cancer.

http://www.wikidata.org/entity/Q37158228

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeted therapeutic agents for colorectal cancer.

@en

Targeted therapeutic agents for colorectal cancer.

@nl

type

label

Targeted therapeutic agents for colorectal cancer.

@en

Targeted therapeutic agents for colorectal cancer.

@nl

prefLabel

Targeted therapeutic agents for colorectal cancer.

@en

Targeted therapeutic agents for colorectal cancer.

@nl

P1433

Q37158228-E63FB81E-0241-4AC6-9F80-6DFAF8312283

P1476

Q37158228-D0DFF2C0-0CA7-4B7E-B03B-8389B0A4C9E8

P2093

Q37158228-63470E19-E484-4E83-AB3E-459F89F290F5

Q37158228-86D8660A-E2AC-4798-932E-9CE5373D9E98

P2860

Q37158228-13B8E9A6-7F2F-4A8D-B343-0A7D802C8FD8

Q37158228-140EC5A0-0370-4482-9E33-F93D5230400A

Q37158228-16547EF8-9CAF-4410-BAF8-020BCF9A9BE6

Q37158228-1868EA0D-0F18-40D2-8C91-0F4166190687

Q37158228-1A8FBC05-E1F7-4B8C-97C0-D9FC9CA18269

Q37158228-1E2B9FF4-A4FE-491D-800A-BE6CD0D84DC9

Q37158228-222AFAE5-8B7F-4F5A-827E-5952E062A1CC

Q37158228-22B8C55D-059B-4C6B-B969-2494609AA0B8

Q37158228-23730FFA-CF32-4D16-AA6E-46CF46358EF4

Q37158228-2BE05F04-B9A7-4CB6-B0D9-B98F1C8122C5

P304

Q37158228-9FC263CB-6762-4B95-A2CA-1D103952B79E

P31

Q37158228-9DF28B47-4BCC-4E33-BBF7-5D4E694A87B2

P356

Q37158228-14729906-57B2-409C-AEB1-C9D1E34AB429

P433

Q37158228-FEA127FE-0D9C-4666-96FF-D3A2D00A255F

P478

Q37158228-EC651E6B-0C02-41A6-87AF-C5F651F513A4

P577

Q37158228-7A8DAD0A-1B25-458D-9A63-7C5CA449636F

P698

Q37158228-68066BA7-06BF-4DC1-BBFF-DD523D824D99

P921

Q37158228-157C9DEA-3F1E-462A-A11A-1393692D9489

P932

Q37158228-00B212A6-BDAF-48E9-8B90-646D2D9CC942

P356

J.GTC.2010.08.017

P1433

Gastroenterology Clinics of North America

P1476

Targeted therapeutic agents for colorectal cancer.

@en

P2093

Cheng E Chee

http://www.w3.org/2001/XMLSchema#string

Frank A Sinicrope

http://www.w3.org/2001/XMLSchema#string

P2860

Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial

Anti-angiogenic therapies for metastatic colorectal cancer

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Cetuximab for the treatment of colorectal cancer.

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

A genetic model for colorectal tumorigenesis

P304

601-613

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.GTC.2010.08.017

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20951919

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3767979

http://www.w3.org/2001/XMLSchema#string